An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project

Background Even though there is no curative treatment for Alzheimer’s disease (AD) yet, an accurate diagnosis is essential, as it is a starting point to arrange proper care, which in turn may lead to beneficial health outcomes. Amyloid‐PET contributes to an accurate diagnosis and we hypothesize that...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2021-12, Vol.17 (S4), p.n/a
Hauptverfasser: van der Flier, Wiesje M, Van Maurik, Ingrid S., Mank, Arenda, Bakker, Els D., de Wilde, Arno, Bouwman, Femke H., Stephens, Andrew W., Van Berckel, Bart N.M., Scheltens, Philip
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue S4
container_start_page
container_title Alzheimer's & dementia
container_volume 17
creator van der Flier, Wiesje M
Van Maurik, Ingrid S.
Mank, Arenda
Bakker, Els D.
de Wilde, Arno
Bouwman, Femke H.
Stephens, Andrew W.
Van Berckel, Bart N.M.
Scheltens, Philip
description Background Even though there is no curative treatment for Alzheimer’s disease (AD) yet, an accurate diagnosis is essential, as it is a starting point to arrange proper care, which in turn may lead to beneficial health outcomes. Amyloid‐PET contributes to an accurate diagnosis and we hypothesize that this predisposes toward a more benign disease trajectory in terms of rate of institutionalization and mortality. Method We included consecutive patients who had their baseline visit at the Alzheimer center Amsterdam between 2015 and 2016. During this period, we offered amyloid‐PET to all participants. Patient underwent amyloid‐PET as part of their diagnostic work‐up and were propensity score matched with patients without amyloid‐PET (i.e. no‐PET). Propensity score matching was performed with nearest neighbor 1‐to‐1 matching without replacement and based on baseline characteristics, resulting in two matched groups of n=444 patients each. The endpoints of the study were admission to a nursing home and mortality retrieved from statistics Netherlands. Result Patients (matched cohort) had a mean age of 64±8, 40% (n=353) female, MMSE 25±4 and 43% (n=379) had dementia at baseline. Mean follow‐up duration was 3±1 for institutionalization and 4±1 for mortality. In the amyloid‐PET group, 10% (n=45) of patients were admitted to a nursing home, compared to 21% (n=92) of no‐PET patients. The amyloid‐PET group (HR=0.48 [0.33‐0.70]) had a lower risk of institutionalization compared to no‐PET patients, corresponding to a 1.5 year delay in institutionalization. Moreover, patients with amyloid‐PET had a lower mortality rate compared to matched no‐PET patients (11% (n=49) vs 18% (n=81); HR=0.51 [0.36‐0.73]), which corresponds with a 1.4 year longer survival. We found no differences between amyloid‐positive and amyloid negative patients). Conclusion We demonstrated that a more accurate diagnosis, operationalized by means of adding amyloid‐PET to the diagnostic work‐up, positively influenced time to institutionalization and death in memory clinic patients, independent of syndrome diagnosis. This provides evidence for the notion that a well‐informed patient has better health outcomes.
doi_str_mv 10.1002/alz.050279
format Article
fullrecord <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_alz_050279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ALZ050279</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1139-381aad291cabd57f55717378c54a25ab44a9260285908301ca1d7106ed405d383</originalsourceid><addsrcrecordid>eNp9kMFKw0AQhhdRsFYvPsGehdSZJNsk3mJttRDQQ714CZPdrW5Js7K7RdKnN6XFo6f5Gb5_GD7GbhEmCBDfU7ufgIA4K87YCIWIIzHk8788hUt25f0GIIUcxYg1ZcdJyp2joLky9NlZbzyXtgvONLugPQ-WK91SrxU3nQ8m7IKxHbVmT4fAqVN8a10YNqF_4KsvzcvH5dOcvzm70TJcs4s1tV7fnOaYvS_mq9lLVL0-L2dlFUnEpIiSHIlUXKCkRolsLUSGWZLlUqQUC2rSlIrh_zgXBeQJDBiqDGGqVQpCJXkyZnfHu9JZ751e19_ObMn1NUJ9sFMPduqjnQHGI_xjWt3_Q9Zl9XHq_AKFw2dY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project</title><source>Wiley Online Library All Journals</source><creator>van der Flier, Wiesje M ; Van Maurik, Ingrid S. ; Mank, Arenda ; Bakker, Els D. ; de Wilde, Arno ; Bouwman, Femke H. ; Stephens, Andrew W. ; Van Berckel, Bart N.M. ; Scheltens, Philip</creator><creatorcontrib>van der Flier, Wiesje M ; Van Maurik, Ingrid S. ; Mank, Arenda ; Bakker, Els D. ; de Wilde, Arno ; Bouwman, Femke H. ; Stephens, Andrew W. ; Van Berckel, Bart N.M. ; Scheltens, Philip</creatorcontrib><description>Background Even though there is no curative treatment for Alzheimer’s disease (AD) yet, an accurate diagnosis is essential, as it is a starting point to arrange proper care, which in turn may lead to beneficial health outcomes. Amyloid‐PET contributes to an accurate diagnosis and we hypothesize that this predisposes toward a more benign disease trajectory in terms of rate of institutionalization and mortality. Method We included consecutive patients who had their baseline visit at the Alzheimer center Amsterdam between 2015 and 2016. During this period, we offered amyloid‐PET to all participants. Patient underwent amyloid‐PET as part of their diagnostic work‐up and were propensity score matched with patients without amyloid‐PET (i.e. no‐PET). Propensity score matching was performed with nearest neighbor 1‐to‐1 matching without replacement and based on baseline characteristics, resulting in two matched groups of n=444 patients each. The endpoints of the study were admission to a nursing home and mortality retrieved from statistics Netherlands. Result Patients (matched cohort) had a mean age of 64±8, 40% (n=353) female, MMSE 25±4 and 43% (n=379) had dementia at baseline. Mean follow‐up duration was 3±1 for institutionalization and 4±1 for mortality. In the amyloid‐PET group, 10% (n=45) of patients were admitted to a nursing home, compared to 21% (n=92) of no‐PET patients. The amyloid‐PET group (HR=0.48 [0.33‐0.70]) had a lower risk of institutionalization compared to no‐PET patients, corresponding to a 1.5 year delay in institutionalization. Moreover, patients with amyloid‐PET had a lower mortality rate compared to matched no‐PET patients (11% (n=49) vs 18% (n=81); HR=0.51 [0.36‐0.73]), which corresponds with a 1.4 year longer survival. We found no differences between amyloid‐positive and amyloid negative patients). Conclusion We demonstrated that a more accurate diagnosis, operationalized by means of adding amyloid‐PET to the diagnostic work‐up, positively influenced time to institutionalization and death in memory clinic patients, independent of syndrome diagnosis. This provides evidence for the notion that a well‐informed patient has better health outcomes.</description><identifier>ISSN: 1552-5260</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1002/alz.050279</identifier><language>eng</language><ispartof>Alzheimer's &amp; dementia, 2021-12, Vol.17 (S4), p.n/a</ispartof><rights>2021 the Alzheimer's Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Falz.050279$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Falz.050279$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids></links><search><creatorcontrib>van der Flier, Wiesje M</creatorcontrib><creatorcontrib>Van Maurik, Ingrid S.</creatorcontrib><creatorcontrib>Mank, Arenda</creatorcontrib><creatorcontrib>Bakker, Els D.</creatorcontrib><creatorcontrib>de Wilde, Arno</creatorcontrib><creatorcontrib>Bouwman, Femke H.</creatorcontrib><creatorcontrib>Stephens, Andrew W.</creatorcontrib><creatorcontrib>Van Berckel, Bart N.M.</creatorcontrib><creatorcontrib>Scheltens, Philip</creatorcontrib><title>An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project</title><title>Alzheimer's &amp; dementia</title><description>Background Even though there is no curative treatment for Alzheimer’s disease (AD) yet, an accurate diagnosis is essential, as it is a starting point to arrange proper care, which in turn may lead to beneficial health outcomes. Amyloid‐PET contributes to an accurate diagnosis and we hypothesize that this predisposes toward a more benign disease trajectory in terms of rate of institutionalization and mortality. Method We included consecutive patients who had their baseline visit at the Alzheimer center Amsterdam between 2015 and 2016. During this period, we offered amyloid‐PET to all participants. Patient underwent amyloid‐PET as part of their diagnostic work‐up and were propensity score matched with patients without amyloid‐PET (i.e. no‐PET). Propensity score matching was performed with nearest neighbor 1‐to‐1 matching without replacement and based on baseline characteristics, resulting in two matched groups of n=444 patients each. The endpoints of the study were admission to a nursing home and mortality retrieved from statistics Netherlands. Result Patients (matched cohort) had a mean age of 64±8, 40% (n=353) female, MMSE 25±4 and 43% (n=379) had dementia at baseline. Mean follow‐up duration was 3±1 for institutionalization and 4±1 for mortality. In the amyloid‐PET group, 10% (n=45) of patients were admitted to a nursing home, compared to 21% (n=92) of no‐PET patients. The amyloid‐PET group (HR=0.48 [0.33‐0.70]) had a lower risk of institutionalization compared to no‐PET patients, corresponding to a 1.5 year delay in institutionalization. Moreover, patients with amyloid‐PET had a lower mortality rate compared to matched no‐PET patients (11% (n=49) vs 18% (n=81); HR=0.51 [0.36‐0.73]), which corresponds with a 1.4 year longer survival. We found no differences between amyloid‐positive and amyloid negative patients). Conclusion We demonstrated that a more accurate diagnosis, operationalized by means of adding amyloid‐PET to the diagnostic work‐up, positively influenced time to institutionalization and death in memory clinic patients, independent of syndrome diagnosis. This provides evidence for the notion that a well‐informed patient has better health outcomes.</description><issn>1552-5260</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMFKw0AQhhdRsFYvPsGehdSZJNsk3mJttRDQQ714CZPdrW5Js7K7RdKnN6XFo6f5Gb5_GD7GbhEmCBDfU7ufgIA4K87YCIWIIzHk8788hUt25f0GIIUcxYg1ZcdJyp2joLky9NlZbzyXtgvONLugPQ-WK91SrxU3nQ8m7IKxHbVmT4fAqVN8a10YNqF_4KsvzcvH5dOcvzm70TJcs4s1tV7fnOaYvS_mq9lLVL0-L2dlFUnEpIiSHIlUXKCkRolsLUSGWZLlUqQUC2rSlIrh_zgXBeQJDBiqDGGqVQpCJXkyZnfHu9JZ751e19_ObMn1NUJ9sFMPduqjnQHGI_xjWt3_Q9Zl9XHq_AKFw2dY</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>van der Flier, Wiesje M</creator><creator>Van Maurik, Ingrid S.</creator><creator>Mank, Arenda</creator><creator>Bakker, Els D.</creator><creator>de Wilde, Arno</creator><creator>Bouwman, Femke H.</creator><creator>Stephens, Andrew W.</creator><creator>Van Berckel, Bart N.M.</creator><creator>Scheltens, Philip</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>202112</creationdate><title>An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project</title><author>van der Flier, Wiesje M ; Van Maurik, Ingrid S. ; Mank, Arenda ; Bakker, Els D. ; de Wilde, Arno ; Bouwman, Femke H. ; Stephens, Andrew W. ; Van Berckel, Bart N.M. ; Scheltens, Philip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1139-381aad291cabd57f55717378c54a25ab44a9260285908301ca1d7106ed405d383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Flier, Wiesje M</creatorcontrib><creatorcontrib>Van Maurik, Ingrid S.</creatorcontrib><creatorcontrib>Mank, Arenda</creatorcontrib><creatorcontrib>Bakker, Els D.</creatorcontrib><creatorcontrib>de Wilde, Arno</creatorcontrib><creatorcontrib>Bouwman, Femke H.</creatorcontrib><creatorcontrib>Stephens, Andrew W.</creatorcontrib><creatorcontrib>Van Berckel, Bart N.M.</creatorcontrib><creatorcontrib>Scheltens, Philip</creatorcontrib><collection>CrossRef</collection><jtitle>Alzheimer's &amp; dementia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Flier, Wiesje M</au><au>Van Maurik, Ingrid S.</au><au>Mank, Arenda</au><au>Bakker, Els D.</au><au>de Wilde, Arno</au><au>Bouwman, Femke H.</au><au>Stephens, Andrew W.</au><au>Van Berckel, Bart N.M.</au><au>Scheltens, Philip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project</atitle><jtitle>Alzheimer's &amp; dementia</jtitle><date>2021-12</date><risdate>2021</risdate><volume>17</volume><issue>S4</issue><epage>n/a</epage><issn>1552-5260</issn><eissn>1552-5279</eissn><abstract>Background Even though there is no curative treatment for Alzheimer’s disease (AD) yet, an accurate diagnosis is essential, as it is a starting point to arrange proper care, which in turn may lead to beneficial health outcomes. Amyloid‐PET contributes to an accurate diagnosis and we hypothesize that this predisposes toward a more benign disease trajectory in terms of rate of institutionalization and mortality. Method We included consecutive patients who had their baseline visit at the Alzheimer center Amsterdam between 2015 and 2016. During this period, we offered amyloid‐PET to all participants. Patient underwent amyloid‐PET as part of their diagnostic work‐up and were propensity score matched with patients without amyloid‐PET (i.e. no‐PET). Propensity score matching was performed with nearest neighbor 1‐to‐1 matching without replacement and based on baseline characteristics, resulting in two matched groups of n=444 patients each. The endpoints of the study were admission to a nursing home and mortality retrieved from statistics Netherlands. Result Patients (matched cohort) had a mean age of 64±8, 40% (n=353) female, MMSE 25±4 and 43% (n=379) had dementia at baseline. Mean follow‐up duration was 3±1 for institutionalization and 4±1 for mortality. In the amyloid‐PET group, 10% (n=45) of patients were admitted to a nursing home, compared to 21% (n=92) of no‐PET patients. The amyloid‐PET group (HR=0.48 [0.33‐0.70]) had a lower risk of institutionalization compared to no‐PET patients, corresponding to a 1.5 year delay in institutionalization. Moreover, patients with amyloid‐PET had a lower mortality rate compared to matched no‐PET patients (11% (n=49) vs 18% (n=81); HR=0.51 [0.36‐0.73]), which corresponds with a 1.4 year longer survival. We found no differences between amyloid‐positive and amyloid negative patients). Conclusion We demonstrated that a more accurate diagnosis, operationalized by means of adding amyloid‐PET to the diagnostic work‐up, positively influenced time to institutionalization and death in memory clinic patients, independent of syndrome diagnosis. This provides evidence for the notion that a well‐informed patient has better health outcomes.</abstract><doi>10.1002/alz.050279</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1552-5260
ispartof Alzheimer's & dementia, 2021-12, Vol.17 (S4), p.n/a
issn 1552-5260
1552-5279
language eng
recordid cdi_crossref_primary_10_1002_alz_050279
source Wiley Online Library All Journals
title An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T03%3A29%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20accurate%20diagnosis%20contributes%20to%20delayed%20institutionalization%20and%20mortality:%20The%20ABIDE%20Project&rft.jtitle=Alzheimer's%20&%20dementia&rft.au=van%20der%20Flier,%20Wiesje%20M&rft.date=2021-12&rft.volume=17&rft.issue=S4&rft.epage=n/a&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1002/alz.050279&rft_dat=%3Cwiley_cross%3EALZ050279%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true